Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

44 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
ATM-Deficient Cancers Provide New Opportunities for Precision Oncology.
Jette NR, Kumar M, Radhamani S, Arthur G, Goutam S, Yip S, Kolinsky M, Williams GJ, Bose P, Lees-Miller SP. Jette NR, et al. Among authors: kolinsky m. Cancers (Basel). 2020 Mar 14;12(3):687. doi: 10.3390/cancers12030687. Cancers (Basel). 2020. PMID: 32183301 Free PMC article. Review.
Pembrolizumab Plus Olaparib for Patients With Previously Treated and Biomarker-Unselected Metastatic Castration-Resistant Prostate Cancer: The Randomized, Open-Label, Phase III KEYLYNK-010 Trial.
Antonarakis ES, Park SH, Goh JC, Shin SJ, Lee JL, Mehra N, McDermott R, Sala-Gonzalez N, Fong PC, Greil R, Retz M, Sade JP, Yanez P, Huang YH, Begbie SD, Gafanov RA, De Santis M, Rosenbaum E, Kolinsky MP, Rey F, Chiu KY, Roubaud G, Kramer G, Sumitomo M, Massari F, Suzuki H, Qiu P, Zhang J, Kim J, Poehlein CH, Yu EY. Antonarakis ES, et al. Among authors: kolinsky mp. J Clin Oncol. 2023 Aug 1;41(22):3839-3850. doi: 10.1200/JCO.23.00233. Epub 2023 Jun 8. J Clin Oncol. 2023. PMID: 37290035 Free PMC article. Clinical Trial.
Corrigendum to "Pembrolizumab plus Olaparib in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort A Study" [Eur Urol 83 (2023) 15-26].
Yu EY, Piulats JM, Gravis G, Fong PCC, Todenhöfer T, Laguerre B, Arranz JA, Oudard S, Massard C, Heinzelbecker J, Nordquist LT, Carles J, Kolinsky MP, Augustin M, Gurney H, Tafreshi A, Li XT, Qiu P, Poehlein CH, Schloss C, de Bono JS. Yu EY, et al. Among authors: kolinsky mp. Eur Urol. 2023 Mar;83(3):e87. doi: 10.1016/j.eururo.2022.11.025. Epub 2022 Dec 15. Eur Urol. 2023. PMID: 36528479 Free article. No abstract available.
Disparities in prostate cancer screening, diagnoses, management, and outcomes between Indigenous and non-Indigenous men in a universal health care system.
Kiciak A, Clark W, Uhlich M, Letendre A, Littlechild R, Lightning P, Vasquez C, Singh R, Broomfield S, Martin AM, Huang G, Fairey A, Kolinsky M, Wallis CJD, Fung C, Hyndman E, Yip S, Bismar TA, Lewis J, Ghosh S, Kinnaird A. Kiciak A, et al. Among authors: kolinsky m. Cancer. 2023 Sep 15;129(18):2864-2870. doi: 10.1002/cncr.34812. Epub 2023 Jul 10. Cancer. 2023. PMID: 37424308
Genetic testing practices among specialist physicians who treat prostate cancer A Canadian, cross-sectional survey.
Yip SM, Morash C, Kolinsky MP, Kapoor A, Ong M, Selvarajah S, Nuk J, Compton K, Pouliot F, Lavallée LT, Khalaf DJ, Hamilton RJ, Gotto GT, Rendon RA, Antebi E, Hotte SJ, Malone S, Chi KN, Drachenberg DE, Saad F, Chan J, Ferrario C, Ko J, Shayegan B, Parimi S, So AI, Feifer A, Jansz K, Finch D, Chin JL, Osborne B, Ho KF, Galamo CD, Zardan A, Niazi T. Yip SM, et al. Among authors: kolinsky mp. Can Urol Assoc J. 2023 Oct;17(10):326-336. doi: 10.5489/cuaj.8403. Can Urol Assoc J. 2023. PMID: 37494316 Free PMC article.
2023 Canadian Urological Association guideline: Genetic testing in prostate cancer.
Rendon RA, Selvarajah S, Wyatt AW, Kolinsky M, Schrader KA, Fleshner NE, Kinnaird A, Merrimen J, Niazi T, Saad F, Shayegan B, Wood L, Chi KN, Black P, Sridhar S, Yip S. Rendon RA, et al. Among authors: kolinsky m. Can Urol Assoc J. 2023 Oct;17(10):314-325. doi: 10.5489/cuaj.8588. Can Urol Assoc J. 2023. PMID: 37851913 Free PMC article. No abstract available.
Tumor Genomic Testing for >4,000 Men with Metastatic Castration-resistant Prostate Cancer in the Phase III Trial PROfound (Olaparib).
Hussain M, Corcoran C, Sibilla C, Fizazi K, Saad F, Shore N, Sandhu S, Mateo J, Olmos D, Mehra N, Kolinsky MP, Roubaud G, Özgüroǧlu M, Matsubara N, Gedye C, Choi YD, Padua C, Kohlmann A, Huisden R, Elvin JA, Kang J, Adelman CA, Allen A, Poehlein C, de Bono J. Hussain M, et al. Among authors: kolinsky mp. Clin Cancer Res. 2022 Apr 14;28(8):1518-1530. doi: 10.1158/1078-0432.CCR-21-3940. Clin Cancer Res. 2022. PMID: 35091440 Clinical Trial.
Olaparib tolerability and common adverse-event management in patients with metastatic castration-resistant prostate cancer: Further analyses from the PROfound study.
Roubaud G, Özgüroğlu M, Penel N, Matsubara N, Mehra N, Kolinsky MP, Procopio G, Feyerabend S, Joung JY, Gravis G, Nishimura K, Gedye C, Padua C, Shore N, Thiery-Vuillemin A, Saad F, van Alphen R, Carducci MA, Desai C, Brickel N, Poehlein C, Del Rosario P, Fizazi K. Roubaud G, et al. Among authors: kolinsky mp. Eur J Cancer. 2022 Jul;170:73-84. doi: 10.1016/j.ejca.2022.04.016. Epub 2022 May 19. Eur J Cancer. 2022. PMID: 35598359 Free article. Clinical Trial.
44 results